Dr. Reddy’s Laboratories Limited (NYSE:RDY) Shares Purchased by PDS Planning Inc

PDS Planning Inc boosted its position in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 6.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,239 shares of the company’s stock after acquiring an additional 309 shares during the quarter. PDS Planning Inc’s holdings in Dr. Reddy’s Laboratories were worth $365,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. FSC Wealth Advisors LLC acquired a new stake in Dr. Reddy’s Laboratories in the third quarter valued at about $40,000. CWM LLC increased its holdings in Dr. Reddy’s Laboratories by 37.9% in the fourth quarter. CWM LLC now owns 2,174 shares of the company’s stock valued at $151,000 after buying an additional 598 shares in the last quarter. Blue Trust Inc. increased its holdings in Dr. Reddy’s Laboratories by 77.3% in the fourth quarter. Blue Trust Inc. now owns 3,378 shares of the company’s stock valued at $227,000 after buying an additional 1,473 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Dr. Reddy’s Laboratories by 19.1% in the fourth quarter. Lindbrook Capital LLC now owns 3,519 shares of the company’s stock valued at $245,000 after buying an additional 565 shares in the last quarter. Finally, Advisors Preferred LLC purchased a new position in Dr. Reddy’s Laboratories in the fourth quarter valued at about $258,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY traded down $0.45 during mid-day trading on Tuesday, reaching $71.70. 47,093 shares of the company’s stock were exchanged, compared to its average volume of 190,723. The company has a quick ratio of 1.90, a current ratio of 2.55 and a debt-to-equity ratio of 0.02. The company has a 50-day simple moving average of $74.37 and a two-hundred day simple moving average of $70.31. Dr. Reddy’s Laboratories Limited has a 52-week low of $53.12 and a 52-week high of $77.72. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 1.77 and a beta of 0.58.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11. Dr. Reddy’s Laboratories had a net margin of 19.26% and a return on equity of 20.97%. The business had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $827.81 million. On average, sell-side analysts predict that Dr. Reddy’s Laboratories Limited will post 3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

RDY has been the subject of a number of research analyst reports. Jefferies Financial Group cut shares of Dr. Reddy’s Laboratories from a “buy” rating to an “underperform” rating in a report on Thursday, January 11th. StockNews.com raised shares of Dr. Reddy’s Laboratories from a “buy” rating to a “strong-buy” rating in a report on Friday, April 5th. Finally, Barclays increased their target price on shares of Dr. Reddy’s Laboratories from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, January 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $80.00.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.